Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Following after are RSV vaccines from Johnson & Johnson as well ... It will compete with Sobi's Synagis (palivizumab), an antibody originated by AZ, which is dosed once a month.

One dose of any of these three vaccines will complete your vaccination. The monoclonal antibodies palivizumab (Synagis) and nirsevimab (Beyfortus), are recommended for infants who are too young ...

As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...

The development of RSV vaccines presents specific challenges, and their clinical use is currently a distant prospect. Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal ...

Sanofi's head of vaccine Thomas Triomphe said the ACIP decision ... which is a follow-up to AZ's older RSV antibody Synagis (palivizumab), now sold by Sobi. The latter drug is restricted to ...

A similar antibody treatment injection, called Synagis, has been available for infants at especially high-risk for RSV since 1998. You can get an RSV vaccine from your physician or local retail ...

A similar antibody treatment injection, called Synagis, has been available for infants at especially high-risk for RSV since 1998. You can get an RSV vaccine from your physician or local retail ...

Synagis is administered as a monthly injection during RSV ... Recent research advancements have introduced RSV vaccines and monoclonal antibodies that protect specific populations from serious ...

There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...

While Robert F. Kennedy Jr., President Donald Trump’s pick to lead the US Department of Health and Human Services, has backpedaled on his anti-vaccine rhetoric during his Senate confirmation ...